Comella, P., Massidda, B., Natale, D., Filippelli, G., Farris, A., Palmeri, S., et al. (2009). “Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience”. In Annals of Oncology (pp.viii119-viii119).
“Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience”
PALMERI, Sergio;
2009-01-01
File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
viii119 L24 Ann Oncol 2009 Palmeri.pdf
Solo gestori archvio
Dimensione
309.35 kB
Formato
Adobe PDF
|
309.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.